ABSORB EXTEND Clinical Investigation: A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions

Trial Profile

ABSORB EXTEND Clinical Investigation: A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ABSORB EXTEND
  • Sponsors Abbott Vascular
  • Most Recent Events

    • 23 Jan 2015 Last checked against ClinicalTrials.gov record.
    • 17 Dec 2013 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov
    • 17 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top